Key terms
About UTHR
United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest UTHR news
Mar 07
7:20am ET
Analysts Are Bullish on Top Healthcare Stocks: DarioHealth (DRIO), United Therapeutics (UTHR)
Mar 07
7:09am ET
United Therapeutics price target raised to $325 from $309 at Wells Fargo
Feb 25
11:50pm ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Exact Sciences (EXAS), United Therapeutics (UTHR) and Ionis Pharmaceuticals (IONS)
Feb 22
2:00pm ET
United Therapeutics price target lowered to $262 from $264 at Ladenburg
Feb 22
7:11am ET
Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), Arcus Biosciences (RCUS) and United Therapeutics (UTHR)
Feb 22
7:07am ET
United Therapeutics: A Balanced Hold Amid Growth and Market Challenges
Feb 22
6:20am ET
Analysts Conflicted on These Healthcare Names: Siemens Healthineers AG (OtherSEMHF), Gilead Sciences (GILD) and United Therapeutics (UTHR)
Feb 21
6:50pm ET
Analysts Are Bullish on These Healthcare Stocks: Bausch + Lomb Corporation (BLCO), Integra Lifesciences (IART)
Feb 21
2:15pm ET
Buy Rating on United Therapeutics: Robust Q4 Earnings and Strong Tyvaso Sales Fuel Positive Outlook
Feb 21
6:23am ET
United Therapeutics Sues FDA Over Liquidia’s Drug Expansion
Feb 21
6:07am ET
United Therapeutics commences litigation with FDA on drug review process
Feb 21
6:05am ET
United Therapeutics reports Q4 EPS $4.36, consensus $4.19
Feb 20
8:25pm ET
Notable companies reporting before tomorrow’s open
Feb 20
1:12pm ET
Notable companies reporting before tomorrow’s open
Feb 12
9:46am ET
Rivian downgraded, Loweâs upgraded: Wall Street’s top analyst calls
Feb 12
4:36am ET
United Therapeutics upgraded to Neutral from Sell at Goldman Sachs
Feb 12
4:15am ET
Equilibrium Valuation: Hold Rating on United Therapeutics amidst Market Challenges and Pipeline Uncertainties
Feb 05
10:10am ET
Charter downgraded, Cigna upgraded: Wall Street’s top analyst calls
Feb 05
6:18am ET
United Therapeutics initiated with an Outperform at Leerink
Jan 11
8:20am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Jan 08
8:31am ET
Liquidia files response and counterclaims to United Therapeutics lawsuit
Jan 07
5:49am ET
United Therapeutics (UTHR) Gets a Hold from BTIG
Jan 02
9:54am ET
BTIG Reaffirms Their Hold Rating on United Therapeutics (UTHR)
Dec 31
5:27am ET
United Therapeutics (UTHR) Receives a Hold from BTIG
Dec 22
11:14am ET
Biotech Alert: Searches spiking for these stocks today
Dec 21
7:40am ET
Analysts Offer Insights on Healthcare Companies: Shockwave Medical (SWAV), Annexon Biosciences (ANNX) and United Therapeutics (UTHR)
Dec 21
6:50am ET
Liquidia price target raised to $30 from $15 at Ladenburg
Dec 21
6:21am ET
United stock negative reaction ‘discounting extreme scenarios,’ says Oppenheimer
Dec 21
6:09am ET
Wells Fargo sees limited fundamental impact to United following Liquidia ruling
Dec 21
5:50am ET
Analysts Are Bullish on These Healthcare Stocks: Bluebird Bio (BLUE), United Therapeutics (UTHR)
Dec 20
5:00pm ET
Liquidia says Court of Appeals affirms PTAB decision to invalidate patent
No recent news articles are available for UTHR
No recent press releases are available for UTHR
UTHR Financials
Key terms
Ad Feedback
UTHR Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
UTHR Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range